MAPT and Alzheimer disease: To meet the needs of the rapidly evolving AD field, cognitive assessment instruments must demonstrate sufficient scientific rigor including robust sensitivity, specificity, and predictive utility among culturally diverse populations, and importantly, be correlated to definitive AD biomarkers such as β-amyloid and phosphorylated tau (pTau-181) (8).